Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma [Corrigendum]

Chen CT, Chuang CH, Hsu CH, Shao YY. J Hepatocell Carcinoma. 2025;12:2341–2346. https://doi.org/10.2147/JHC.S548785 The authors have advised Figure 1B on page 2344 of the published paper is incorrect. Due to an error that occurred inadvertently at the time of figure assembly, Figure 1B was a duplicate of Figure 2B. The correct Figure 1 is shown below. Figure 1 (A) Overall survival (OS) and (B) progression-free survival (PFS) of patients who received immune checkpoint inhibitors (ICIs) segmented into groups on the basis of whether they exhibited early protein induced by vitamin K absence/antagonists-II (PIVKA-II) response. The authors apologize for this error and advise it does not affect the results of the paper.